Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

MediPharm Labs Corp. (T:LABS)

Business Focus: Alternative Medicine

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LABS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 16, 2022 07:00 ET
MediPharm Labs Reports First Quarter Results
TORONTO, May 16, 2022 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2022.
Read full article
May 16, 2022 07:00 ET
MediPharm Labs Reports First Quarter Results
TORONTO, May 16, 2022 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2022.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.90
--
--
Price to Sales - TTM
0.97
2.82
4.28
Price to Book - most recent quarter
0.27
0.99
1.80
Price to Cash Flow per share - TTM
--
11.75
9.43
Price to Free Cash Flow per share - TTM
--
7.11
18.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 20227,388,720798,794
May 31, 20226,589,926-1,027,614
May 15, 20227,617,540153,466
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

MediPharm Labs Corp. is a Canada-based pharmaceutical company that is specialized in cannabis. The Company produces purified, pharmaceutical-like cannabis extracts and related derivative products. The Company formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. It is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The Company's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.

See business summary

 

Twitter

Search (past week) for $LABS.CA

  • No tweets found